These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
158 related items for PubMed ID: 16221871
1. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W, Kelley VR, Relle M, Galle PR. J Am Soc Nephrol; 2005 Nov; 16(11):3264-72. PubMed ID: 16221871 [Abstract] [Full Text] [Related]
2. Inducible co-stimulator null MRL-Faslpr mice: uncoupling of autoantibodies and T cell responses in lupus. Zeller GC, Hirahashi J, Schwarting A, Sharpe AH, Kelley VR. J Am Soc Nephrol; 2006 Jan; 17(1):122-30. PubMed ID: 16291836 [Abstract] [Full Text] [Related]
3. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR. J Immunol; 1998 Jul 01; 161(1):494-503. PubMed ID: 9647261 [Abstract] [Full Text] [Related]
4. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. Pérez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlöndorff D, Luckow B. J Am Soc Nephrol; 2005 Dec 01; 16(12):3592-601. PubMed ID: 16267157 [Abstract] [Full Text] [Related]
5. IFN-gamma limits macrophage expansion in MRL-Fas(lpr) autoimmune interstitial nephritis: a negative regulatory pathway. Schwarting A, Moore K, Wada T, Tesch G, Yoon HJ, Kelley VR. J Immunol; 1998 Apr 15; 160(8):4074-81. PubMed ID: 9558118 [Abstract] [Full Text] [Related]
6. Genomic view of IFN-alpha response in pre-autoimmune NZB/W and MRL/lpr mice. Lu Q, Shen N, Li XM, Chen SL. Genes Immun; 2007 Oct 15; 8(7):590-603. PubMed ID: 17728792 [Abstract] [Full Text] [Related]
7. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice. Yasuda T, Yoshimoto T, Tsubura A, Matsuzawa A. Cell Immunol; 2001 Jun 15; 210(2):77-86. PubMed ID: 11520074 [Abstract] [Full Text] [Related]
8. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. Haas C, Ryffel B, Le Hir M. J Immunol; 1997 Jun 01; 158(11):5484-91. PubMed ID: 9164971 [Abstract] [Full Text] [Related]
10. IK cytokine ameliorates the progression of lupus nephritis in MRL/lpr mice. Muraoka M, Hasegawa H, Kohno M, Inoue A, Miyazaki T, Terada M, Nose M, Yasukawa M. Arthritis Rheum; 2006 Nov 15; 54(11):3591-600. PubMed ID: 17075801 [Abstract] [Full Text] [Related]
11. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog. Choi JY, Gao W, Odegard J, Shiah HS, Kashgarian M, McNiff JM, Baker DC, Cheng YC, Craft J. Arthritis Rheum; 2006 Oct 15; 54(10):3277-83. PubMed ID: 17009262 [Abstract] [Full Text] [Related]
12. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. Faust J, Menke J, Kriegsmann J, Kelley VR, Mayet WJ, Galle PR, Schwarting A. Arthritis Rheum; 2002 Nov 15; 46(11):3083-95. PubMed ID: 12428253 [Abstract] [Full Text] [Related]
13. Skin disease is prevented but nephritis is accelerated by multiple pregnancies in autoimmune MRL/LPR mice. Kökény G, Godó M, Nagy E, Kardos M, Kotsch K, Casalis P, Bodor C, Rosivall L, Volk HD, Zenclussen AC, Hamar P. Lupus; 2007 Nov 15; 16(7):465-77. PubMed ID: 17670844 [Abstract] [Full Text] [Related]
14. Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice. Miyazaki T, Ono M, Qu WM, Zhang MC, Mori S, Nakatsuru S, Nakamura Y, Sawasaki T, Endo Y, Nose M. Eur J Immunol; 2005 May 15; 35(5):1510-20. PubMed ID: 15832294 [Abstract] [Full Text] [Related]
15. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. Patole PS, Gröne HJ, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Schlöndorff D, Anders HJ. J Am Soc Nephrol; 2005 May 15; 16(5):1326-38. PubMed ID: 15772251 [Abstract] [Full Text] [Related]
16. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Shimizu S, Nakashima H, Masutani K, Inoue Y, Miyake K, Akahoshi M, Tanaka Y, Egashira K, Hirakata H, Otsuka T, Harada M. Rheumatology (Oxford); 2004 Sep 15; 43(9):1121-8. PubMed ID: 15213333 [Abstract] [Full Text] [Related]
17. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, Terada M, Hieshima K, Maruyama H, Miyazaki J, Yoshie O, Nose M, Fujita S. Arthritis Rheum; 2003 Sep 15; 48(9):2555-66. PubMed ID: 13130475 [Abstract] [Full Text] [Related]
18. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice. Nicoletti F, Di Marco R, Zaccone P, Xiang M, Magro G, Grasso S, Morrone S, Santoni A, Shoenfeld Y, Garotta G, Meroni P. Eur J Immunol; 2000 Feb 15; 30(2):438-47. PubMed ID: 10671199 [Abstract] [Full Text] [Related]
19. Granulocyte-colony stimulating factor treatment of lupus autoimmune disease in MRL-lpr/lpr mice. Zavala F, Masson A, Hadaya K, Ezine S, Schneider E, Babin O, Bach JF. J Immunol; 1999 Nov 01; 163(9):5125-32. PubMed ID: 10528219 [Abstract] [Full Text] [Related]
20. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Sadanaga A, Nakashima H, Masutani K, Miyake K, Shimizu S, Igawa T, Sugiyama N, Niiro H, Hirakata H, Harada M. Arthritis Rheum; 2005 Dec 01; 52(12):3987-96. PubMed ID: 16320345 [Abstract] [Full Text] [Related] Page: [Next] [New Search]